menu
    • menu
    [{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dazucorilant","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dazucorilant","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Soft gel Capsule","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Dazucorilant","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Corcept Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Dazucorilant

    Menu

    Dazucorilant

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Corcept Announces Phase 2 Data of Dazucorilant in ALS Patients

                            Details : CORT113176 (dazucorilant) is a selective cortisol modulator that binds to the glucocorticoid receptor. It is being developed for amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 11, 2024

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Corcept Completes Enrollment in Phase 2 DAZALS Trial for ALS Patients

                            Details : CORT113176 (dazucorilant) is a selective cortisol modulator under development for amyotrophic lateral sclerosis (ALS), binding to the glucocorticoid receptor but not to other hormone receptors.

                            Product Name : CORT113176

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Corcept Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

                            Details : DAZALS is a 198-patient, randomized, double-blind, placebo-controlled Phase 2 trial of dazucorilant in patients with ALS. The primary endpoints will be ALS Functional Rating Scale-Revised (ALSFRS-R) total score and safety.

                            Product Name : CORT113176

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : Dazucorilant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth